DePalo 1993.

Methods	Multi‐centre RCT
Participants	771 women randomised Women with stage 1 with no myometrial involvement did not receive any adjuvant treatment 138 (17.9%) Median age ranged between 58 and 61 across all MPA and no MPA comparisons (women with R1‐R3). 601 (83%) women had adenocarcinoma histological type, 80 (11%) had adenoacanthoma, 4 (0.5%) had clear cell, 29 (4%) had adenosquamous and 4 (0.5%) women had undifferentiated histology. 399 (55.5%) had myometrial invasion classified as M1, 192 (26.75%) as M2 and 127 (17.75%) classified as M3.
Interventions	Oral Medroxy progesterone 100mg twice daily for 1 year
Outcomes	Overall death rates Endometrial cancer deaths Intercurrent deaths Relapse from disease Adverse events (only reported in the treatment arm)
Notes	Patient withdrawals; disease more than stage 1 on review, patient refusal, intercurrent disease Data only available for intention to treat analysis Progestagen group 327 women Control group 370 women Duration of follow‐up 84 months
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Concealment of allocation is most likely adequate because there was central randomisation, but it is uncertain, "Quality control of data was performed at a centralised data centre".
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	% analysed: 718/718 (100%)
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists